Last update May 31, 2022

Somatostatin

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Somatostatin is a hormonal polypeptide consisting of 14 to 28 amino acids obtained from the hypothalamus or by synthesis. Somatostatin inhibits the release of growth hormone from the anterior pituitary, thyrotropin and corticotropin from the pituitary, glucagon, and insulin from the pancreas, and has a role in the regulation of gastric and duodenal secretions. Used in upper gastrointestinal bleeding (including pancreatic fistulae and esophageal varices), insulin resistance, treatment of hormone-secreting tumors, and other hypersecretory disorders. It has a very short duration of action, unlike several somatostatin analogs such as Octreotide, Pasireotide, and Lanreotide. Intravenous administration.

Since the last update we have not found published data on its excretion in breastmilk.

Its high molecular weight and very rapid elimination half-life (1-3 minutes) make its passage into breast milk very unlikely. Somatostatin is rapidly degraded by peptidase enzymes present in cells and plasma. (Rai 2015)

Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant, except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.

No problems were observed in an infant whose mother was treated with somatostatin analogues during pregnancy and twelve months of lactation. (Babinska 2021)

It is used in neonates and young infants. (Costa 2018, Rimensberger 1998)

Except in the neonatal period, endogenous somatostatin levels increase in response to suckling. (Uvnäs 2020)


See below the information of this related product:

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Somatostatin is also known as


Somatostatin in other languages or writings:

Group

Somatostatin belongs to this group or family:

Tradenames

Main tradenames from several countries containing Somatostatin in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 1.638 daltons
0.02 - 0.05 hours

References

  1. Babinska A, Olszewska H, Sworczak K. Safe treatment with somatostatin analogues in a woman with acromegaly whilst pregnant and lactating. Neuro Endocrinol Lett. 2021 Nov 30;42(7):433-437. Abstract Full text (link to original source) Full text (in our servers)
  2. Uvnäs Moberg K, Ekström-Bergström A, Buckley S, Massarotti C, Pajalic Z, Luegmair K, Kotlowska A, Lengler L, Olza I, Grylka-Baeschlin S, Leahy-Warren P, Hadjigeorgiu E, Villarmea S, Dencker A. Maternal plasma levels of oxytocin during breastfeeding-A systematic review. PLoS One. 2020 Aug 5;15(8):e0235806. Abstract
  3. Costa KM, Saxena AK. Surgical chylothorax in neonates: management and outcomes. World J Pediatr. 2018 Apr;14(2):110-115. Abstract
  4. Rai U, Thrimawithana TR, Valery C, Young SA. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Pharmacol Ther. 2015 Aug;152:98-110. Abstract
  5. Kelly RF, Shumway SJ. Conservative management of postoperative chylothorax using somatostatin. Ann Thorac Surg. 2000 Abstract Full text (in our servers)
  6. Rimensberger PC, Müller-Schenker B, Kalangos A, Beghetti M. Treatment of a persistent postoperative chylothorax with somatostatin. Ann Thorac Surg. 1998 Abstract Full text (in our servers)

Total visits

4,285

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM